Excerpt

Social anxiety disorder is very common and often coexists with other mental health problems. It can be severely detrimental to quality of life, with far-reaching consequences for education, employment and relationships. Only a minority of people with social anxiety disorder receive help, but this guideline demonstrates that effective treatments exist and it aims to increase identification and assessment so that people can access interventions to help them overcome this disabling condition.

The guideline reviews the evidence for the management of social anxiety disorder across the care pathway in adults, children and young people. It reviews evidence for identification and assessment, and compares the effects of pharmacological and psychological interventions. Interventions for adults are compared using a network meta-analysis. The guideline also contains a chapter on improving access to services and the experience of care for people with social anxiety disorder.

Contents

• GUIDELINE DEVELOPMENT GROUP MEMBERS
• ACKNOWLEDGEMENTS
• 1. PREFACE
  • 1.1. NATIONAL GUIDELINE
  • 1.2. THE NATIONAL SOCIAL ANXIETY DISORDER GUIDELINE
• 2. SOCIAL ANXIETY DISORDER
  • 2.1. THE DISORDER
  • 2.2. AETIOLOGY
  • 2.3. TREATMENT AND MANAGEMENT IN THE NHS
  • 2.4. THE ECONOMIC COST OF SOCIAL ANXIETY DISORDER
• 3. METHODS USED TO DEVELOP THIS GUIDELINE
  • 3.1. OVERVIEW
  • 3.2. THE SCOPE
  • 3.3. THE GUIDELINE DEVELOPMENT GROUP
  • 3.4. REVIEW QUESTIONS
  • 3.5. SYSTEMATIC CLINICAL LITERATURE REVIEW
  • 3.6. HEALTH ECONOMICS METHODS
  • 3.7. USING NICE EVIDENCE REVIEWS AND RECOMMENDATIONS FROM EXISTING NICE CLINICAL GUIDELINES
  • 3.8. FROM EVIDENCE TO RECOMMENDATIONS
  • 3.9. STAKEHOLDER CONTRIBUTIONS
  • 3.10. VALIDATION OF THE GUIDELINE
• 4. IMPROVING ACCESS TO SERVICES AND THE EXPERIENCE OF CARE
  • 4.1. INTRODUCTION
  • 4.2. METHOD
  • 4.3. REVIEW OF THE LITERATURE FOR ACCESS TO SERVICES AND EXPERIENCE OF CARE
  • 4.4. DEVELOPING PRINCIPLES OF CARE SPECIFICALLY FOR PEOPLE WITH SOCIAL ANXIETY DISORDER
  • 4.5. FROM EVIDENCE TO RECOMMENDATIONS
  • 4.6. RECOMMENDATIONS
• 5. CASE IDENTIFICATION AND ASSESSMENT
  • 5.1. INTRODUCTION
  • 5.2. CASE IDENTIFICATION
  • 5.3. RECOMMENDATIONS FOR CASE IDENTIFICATION
  • 5.4. ASSESSMENT
  • 5.5. RECOMMENDATIONS FOR ASSESSMENT
• 6. INTERVENTIONS FOR ADULTS
  • 6.1. INTRODUCTION
  • 6.2. CURRENT PRACTICE
  • 6.3. DEFINITIONS AND AIMS OF INTERVENTIONS
  • 6.4. CLINICAL REVIEW PROTOCOL
  • 6.5. OVERVIEW OF STUDIES CONSIDERED AND CLINICAL EVIDENCE
  • 6.6. PHARMACOLOGICAL INTERVENTIONS
  • 6.7. PSYCHOLOGICAL INTERVENTIONS
  • 6.8. COMBINED PSYCHOLOGICAL AND PHARMACOLOGICAL INTERVENTIONS
  • 6.9. SPECIFIC SUBGROUPS
  • 6.10. HEALTH ECONOMIC EVIDENCE
  • 6.11. OVERALL CLINICAL SUMMARY
  • 6.12. FROM EVIDENCE TO RECOMMENDATIONS
  • 6.13. RECOMMENDATIONS
• 7. INTERVENTIONS FOR CHILDREN AND YOUNG PEOPLE
  • 7.1. INTRODUCTION
  • 7.2. CLINICAL REVIEW PROTOCOL
  • 7.3. OVERVIEW OF CLINICAL EVIDENCE
  • 7.4. PHARMACOLOGICAL INTERVENTIONS
  • 7.5. PSYCHOLOGICAL INTERVENTIONS
  • 7.6. CLINICAL EVIDENCE SUMMARY
  • 7.7. HEALTH ECONOMIC EVIDENCE
  • 7.8. FROM EVIDENCE TO RECOMMENDATIONS
  • 7.9. RECOMMENDATIONS
• 8. COMPUTERISED COGNITIVE BEHAVIOURAL THERAPY FOR SPECIFIC PHOBIAS IN ADULTS
  • 8.1. INTRODUCTION
  • 8.2. REVIEW PROTOCOL
  • 8.3. CLINICAL EVIDENCE
  • 8.4. CLINICAL EVIDENCE SUMMARY
  • 8.5. FROM EVIDENCE TO RECOMMENDATIONS
  • 8.6. RECOMMENDATIONS
• 9. SUMMARY OF RECOMMENDATIONS
  • 9.1. GENERAL PRINCIPLES OF CARE IN MENTAL HEALTH AND GENERAL MEDICAL SETTINGS
  • 9.2. IDENTIFICATION AND ASSESSMENT OF ADULTS
  • 9.3. INTERVENTIONS FOR ADULTS WITH SOCIAL ANXIETY DISORDER
  • 9.4. IDENTIFICATION AND ASSESSMENT OF CHILDREN AND YOUNG PEOPLE
  • 9.5. INTERVENTIONS FOR CHILDREN AND YOUNG PEOPLE WITH SOCIAL ANXIETY DISORDER
  • 9.6. INTERVENTIONS THAT ARE NOT RECOMMENDED TO TREAT SOCIAL ANXIETY DISORDER
  • 9.7. SPECIFIC PHOBIAS
• APPENDICES
  • APPENDIX 1. SCOPE FOR THE DEVELOPMENT OF THE CLINICAL GUIDELINE
  • APPENDIX 2. DECLARATIONS OF INTERESTS BY GUIDELINE DEVELOPMENT GROUP MEMBERS
  • APPENDIX 3. SPECIAL ADVISERS TO THE GUIDELINE DEVELOPMENT GROUP
  • APPENDIX 4. STAKEHOLDERS AND EXPERTS WHO SUBMITTED COMMENTS IN RESPONSE TO THE CONSULTATION DRAFT OF THE GUIDELINE
  • APPENDIX 5. RESEARCHERS CONTACTED TO REQUEST FURTHER DATA
  • APPENDIX 6. SEARCH STRATEGIES FOR THE IDENTIFICATION OF CLINICAL EVIDENCE
  • APPENDIX 7. SEARCH STRATEGIES FOR THE IDENTIFICATION OF HEALTH ECONOMIC STUDIES
  • APPENDIX 8. ECONOMIC EVIDENCE: METHODOLOGY CHECKLIST TEMPLATE
  • APPENDIX 9. HIGH-PRIORITY RESEARCH RECOMMENDATIONS
  • APPENDIX 10. COMPLETED METHODOLOGY CHECKLISTS FOR CASE IDENTIFICATION AND ASSESSMENT
  • APPENDIX 11. NETWORK META-ANALYSIS DIAGRAMS AND WINBUGS CODE
  • APPENDIX 12. INTERVENTIONS FOR ADULTS (NETWORK META-ANALYSIS) – STUDY CHARACTERISTICS
  • APPENDIX 13. INTERVENTIONS FOR ADULTS (PAIRWISE ANALYSES) – STUDY CHARACTERISTICS
  • APPENDIX 14. INTERVENTIONS FOR ADULTS – FOREST PLOTS
  • APPENDIX 15. INTERVENTIONS FOR ADULTS – GRADE PROFILES
  • APPENDIX 16. INTERVENTIONS FOR CHILDREN AND YOUNG PEOPLE – STUDY CHARACTERISTICS
  • APPENDIX 17. INTERVENTIONS FOR CHILDREN AND YOUNG PEOPLE – FOREST PLOTS
  • APPENDIX 18. INTERVENTIONS FOR ADULTS (RELAPSE PREVENTION) – STUDY CHARACTERISTICS
  • APPENDIX 19. INTERVENTIONS FOR CHILDREN AND YOUNG PEOPLE – GRADE PROFILES
  • APPENDIX 20. RISK OF BIAS SUMMARIES
  • APPENDIX 21. COMPLETED METHODOLOGY CHECKLISTS – ECONOMIC EVALUATIONS
  • APPENDIX 22. HEALTH ECONOMIC EVIDENCE TABLES
  • APPENDIX 23. DETAILED RESULTS OF GUIDELINE ECONOMIC ANALYSIS
  • APPENDIX 24. ECONOMIC EVIDENCE PROFILE
  • APPENDIX 25. EXCLUDED STUDIES
  • APPENDIX 26. INTERVENTIONS FOR ADULTS (RELAPSE PREVENTION) – FOREST PLOTS
• REFERENCES
• ABBREVIATIONS

The views presented in this book do not necessarily reflect those of the British Psychological Society, and the publishers are not responsible for any error of omission or fact. The British Psychological Society is a registered charity (no. 229642).